New Developments in Retinal Disease Treatments
Everads Therapy, a clinical-stage company focused on retinal disease treatments, is making significant strides with its innovative suprachoroidal delivery technology. This advance has attracted attention due to its potential to revolutionize how conditions like retinal detachments are treated. Recently, Everads announced two exciting oral presentations at the 2025 American Society of Retina Specialists (ASRS) Annual Meeting, showcasing the full results from their first-in-human clinical trial and new preclinical findings.
Clinical Study Highlights
The clinical trial evaluated the Everads Injector's safety and performance for administering a triamcinolone acetonide suspension via the suprachoroidal route in patients dealing with diabetic macular edema. The results were promising, confirming the safety, feasibility, and an overall user-friendly experience for the injector used in an office-based setting.
Executive Chairman, Moshe Weinstein, expressed his enthusiasm: "We're excited to share the full dataset from our clinical trial, demonstrating the safety, tolerability, and performance of our suprachoroidal injector, along with new data supporting its potential use for in-office retinal detachment repair." These findings lay a solid groundwork for advancing future programs utilizing this pioneering delivery platform.
Expanding Treatment Options for Retinal Detachments
As retinal detachment repair presents continuing complexities, there is a pressing need for less invasive and more affordable treatment options. This shift aims to enhance patient recovery durations significantly. In a preclinical study conducted using human cadaver eyes, Dr. Gareth D. Mercer and his colleagues highlighted the Everads Injector's capability to successfully administer viscoelastic substances into the suprachoroidal space. Their results demonstrated a reliable relationship between the volume injected and the size of the resulting buckle, underscoring the technology's innovative potential in non-surgical, in-office interventions.
Upcoming Presentations at ASRS 2025
Attendees at the conference can look forward to two key presentations from Everads:
- Minimally Invasive Suprachoroidal Buckling Using a Novel Injector: Preclinical Evaluation in Human Cadaver Eyes
Presented by Mercer GD et al on July 31st at 8:28 AM in Hall B - First-in-Human Study Using a Novel Suprachoroidal Injector
Presented by Barak Y et al on August 2nd at 4:27 PM in Hall B
About Everads Therapy
Everads Therapy is committed to transforming retinal disease treatment with its proprietary suprachoroidal delivery platform. This platform facilitates swift, broad, and secure drug distribution via non-invasive, office-based injections. Furthermore, the company is actively developing this approach for in-office suprachoroidal buckling (viscopexy) aimed at treating selected retinal detachments. Collaboration with partners spans gene therapy, cell therapy, and various small molecule formulations, all aimed at optimizing the capabilities of this advanced delivery system.
Company Background
Established as a spin-out from DALI Medical Devices, which is recognized for its expertise in injectable drug delivery technologies, Everads is nestled within RAD Biomed, a well-respected biotech accelerator. Its cutting-edge technologies are licensed from the laboratory headed by Prof Y Rotenstreich at the Sheba Tel Hashomer Medical Center.
For further updates and information about Everads Therapy, visit their website.
Frequently Asked Questions
What new findings did Everads present at ASRS 2025?
Everads shared the full results from their first-in-human clinical trial and preclinical data supporting their suprachoroidal injector for retinal treatments.
What is the Everads Injector?
The Everads Injector is a novel device designed for suprachoroidal drug delivery, aiming to treat conditions like diabetic macular edema and retinal detachments with minimal invasiveness.
Why is the suprachoroidal delivery method important?
This method offers a safer, more effective way to administer medications directly to the retinal area, enhancing patient comfort and potentially improving recovery times.
What did the preclinical studies demonstrate?
Preclinical studies showed that the Everads Injector can reliably deliver viscoelastic substances into the suprachoroidal space, indicating its efficacy for treating retinal detachment.
How is Everads Therapy positioned in the industry?
Everads Therapy is at the forefront of retinal disease treatment, innovating with its proprietary technologies and collaborating with various partners in the biotech field.
